Literature DB >> 15044039

Role of dopamine D1 receptors in the striatal and cortical fos expression induced by the muscarinic agonist pilocarpine.

David Wirtshafter1.   

Abstract

Injections of the muscarinic cholinergic receptor agonist pilocarpine (50 mg/kg) induced pronounced expression of the immediate early gene (IEG) product Fos in the striatum and cortex of rats. Pretreatment with the dopamine D1 receptor antagonist 7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-H-3-benzazepine hydrochloride (SCH-23390; 0.2-2.0 mg/kg) drastically attenuated the pilocarpine response in the striatum, but had no effect in the cortex. In contrast, the muscarinic receptor antagonist scopolamine (0.75-3.00 mg/kg) virtually abolished the Fos response at both sites. These results suggest that stimulation of dopamine D1 receptors may mediate the effects of muscarinic agonists on Fos expression in the striatum, but not the cortex.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044039     DOI: 10.1016/j.ejphar.2004.02.025

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  The rate of intravenous cocaine administration alters c-fos mRNA expression and the temporal dynamics of dopamine, but not glutamate, overflow in the striatum.

Authors:  C R Ferrario; M Shou; A N Samaha; C J Watson; R T Kennedy; T E Robinson
Journal:  Brain Res       Date:  2008-03-07       Impact factor: 3.252

2.  Dopamine D2-receptor activation elicits akinesia, rigidity, catalepsy, and tremor in mice expressing hypersensitive {alpha}4 nicotinic receptors via a cholinergic-dependent mechanism.

Authors:  Rubing Zhao-Shea; Bruce N Cohen; Herwig Just; Tristan McClure-Begley; Paul Whiteaker; Sharon R Grady; Outi Salminen; Paul D Gardner; Henry A Lester; Andrew R Tapper
Journal:  FASEB J       Date:  2009-08-31       Impact factor: 5.191

3.  Differential patterns of synaptotagmin7 mRNA expression in rats with kainate- and pilocarpine-induced seizures.

Authors:  Gordana Glavan; Ronald Eugene See; Marko Živin
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.